Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

NCT04319198 ↗

Phase 4 Completed 25 enrolled Gilead Sciences

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).

Timeline

Start: 2020-08-04
Primary completion: 2024-10-18
Completion: 2024-10-18

Publications

Kwapisz D. Sacituzumab Govitecan-hziy in Breast Cancer. Am J Clin Oncol. 2022 Jul 1;45(7):279-285. doi: 10.1097/COC.0000000000000919. Epub 2022 May 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sacituzumab Govitecan	Monoclonal antibody	10 mg/kg	Intravenous

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Summary

Timeline

Publications

Drugs

Indications